Comparing Two Post-Operative Radiotherapy Schedules for Recurrent Prostate Cancer After Surgery 25 Sessions Versus 20 Sessions with Hormone Therapy Option

What this Trial Is About

This research compares two different post-operative salvage radiotherapy schedules for men with recurrent prostate cancer after surgery who have detectable PSA levels. The goal is to determine if a shorter treatment plan is as safe and effective as the standard longer schedule. This study is important because cancer can return in many high-risk patients after prostate surgery, and the best radiotherapy approach, including treatment length and pelvic area coverage, remains under study. Participants will receive either the standard radiotherapy with 25 sessions over about 5 weeks delivering 62.5 Gy to the prostate bed and 45 Gy to the pelvis, or a shorter schedule with 20 sessions over about 4 weeks delivering 52.5 Gy to the prostate bed and 43 Gy to the pelvis. Both groups may also receive hormone therapy Androgen Deprivation Therapy for 6 to 24 months, depending on the doctors discretion. Some patients with pelvic nodal disease may receive additional medications for 24 months following a specific protocol. During the study, participants will be monitored for side effects related to urinary and bowel health for up to 24 months after radiotherapy. Researchers will also assess cancer control through PSA levels and disease spread, survival rates, and quality of life using urinary, bowel, and sexual health questionnaires. Follow-up evaluations will continue for up to 10 years, with assessments at regular intervals to understand long-term outcomes and safety. The entire study is expected to last about 12 years, including 2 years for enrollment and 10 years of follow-up.

Non-inferiority Study Comparing Salvage Pelvic Radiotherapy in 25 Fractions (62.5 Gy/25) Versus 20 Fractions (52.5 Gy/20) for Recurrent Prostate Cancer After Surgery.